Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement

Publisher： Karger

E-ISSN： 2296-5262|24|5|491-494

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.24, Iss.5, 2001-10, pp. : 491-494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 691-693

Karger

Access to resources Recommend Favorite

Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature

By  

Oncology Research and Treatment, Vol. 26, Iss. 4, 2003-09 ,pp. : 351-354

Karger

Access to resources Recommend Favorite

Effective Treatment of Refractory Pulmonary Hemorrhage with Monoclonal Anti-CD20 Antibody (Rituximab)

By  

Respiration, Vol. 78, Iss. 1, 2008-09 ,pp. : 106-109

Karger

Access to resources Recommend Favorite

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite

Rituximab (Anti-CD20 Monoclonal Antibody) Administration in a Young Patient with Resistant B-Prolymphocytic Leukemia

By  

Acta Haematologica, Vol. 102, Iss. 2, 1999-10 ,pp. : 94-98

Karger

Access to resources Recommend Favorite